Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review

详细信息    查看全文

• 作者：Mariko Yabe^a ; ^e ; L. Jeffrey Medeiros^a ; Yahya Daneshbod^b ; Masoud Davanlou^c ; Carlos E. Bueso-Ramos^a ; Elisa J. Moran^d ; Ken H. Young^a ; Roberto N. Miranda^a ; ^{Roberto.miranda@mdanderson.org}
• 关键词：Inflammatory bowel disease ; Autoimmune disorders ; Immunosuppression ; Azathioprine ; 6-Mercaptopurine
• 刊名：Annals of Diagnostic Pathology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：26
• 期：Complete
• 页码：16-22
• 全文大小：968 K
• 卷排序：26

文摘

Hepatosplenic T-cell lymphoma is known to arise in patients with immunodysregulatory disorders, and TNF-α inhibitor therapy has been suggested to increase the risk. However, our experience with 7 patients and additional literature review suggest that TNF-α inhibitor therapy is not essential for the development of HSTCL. Our findings imply that immunosuppressive drugs or other factors are more critical to development of HSTCL in this context.